The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease. (17th February 2020)

• Record Type: Journal Article
• Authors: Fabiani, Claudia; Vitale, Antonio; Rigante, Donato; Emmi, Giacomo; Lopalco, Giuseppe; Di Scala, Gerardo; Sota, Jurgen; Orlando, Ida; Franceschini, Rossella; Frediani, Bruno; Galeazzi, Mauro; Iannone, Florenzo; Tosi, Gian Marco; Cantarini, Luca
• Is Part Of: Ocular immunology and inflammation. Volume 28:Number 2(2020)
• Page Start: 298
• Page End: 304
• Publication Date: 2020-02-17
• Subjects: Anakinra -- biologics -- canakinumab -- treatment -- uveitis; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2018.1511810
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose : To identify factors associated with sustained response to interleukin (IL)-1 inhibition among demographic, clinical and therapeutic data in patients with Behçet disease (BD). Methods : BD patients treated with anakinra or canakinumab were enrolled. Patients were divided into two groups according to the clinical response: group 1 included subjects showing a treatment duration of at least 52 weeks and no secondary inefficacy during the first follow-up year; the remaining patients were included in the group 2. Demographic, clinical and therapeutic data were analyzed to identify significant differences between groups. Results : Eighteen patients were included in group 1 and 18 patients in group 2. A better response to IL-1 inhibitors was significantly more common among patients with BD-related uveitis ( p = 0.006) and patients with a longer disease duration ( p = 0.03). Conclusion : IL-1 blockade is effective in BD, especially in the subset of patients presenting eye involvement and in those with long-lasting disease.